Impact of antiplatelet therapy in heart disease

Advances in Cardiology

Volumn 47, Issue , 2012, Pages 5-19

  Renda, Giulia ^a   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CORONARY RISK; CORONARY STENT; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; HEART DISEASES; HUMANS; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84865793782     PISSN: 00652326     EISSN: 16622839     Source Type: Book Series    
DOI: 10.1159/000338060     Document Type: Article

References (56)

1. Libby P: Inflammation in atherosclerosis. Nature 2002;420:868-874.
2. Lindahl B, et al: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-1147.
3. Liuzzo G, et al: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-424.
4. Ardissino D, et al: Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-771.
5. Badimon L, Fuster V: Arterial thrombosis: a brief overview; in Kristensen S, De Caterina R, Moliterno D (eds): Therapeutic Strategies in Thrombosis. Oxford, Clinical Publishing, 2006, pp 275-300.
6. Patrono C, et al: Expert Position Paper on the Use of Antiplatelet Agents. 2011 Update-the Task Force of the European Society of Cardiology on the Use of Antiplatelet Agents for the Treatment and Prevention of Atherothrombosis. Eur Heart J 2011, in press.
7. Goodman SG, et al: Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 suppl): 708S-775S.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocar-dial infarction: ISIS-2. Lancet 1988;2:349-360.
9. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myo-cardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
10. Van de Werf F, et al: Management of acute myocar-dial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
11. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
12. Sabatine MS, et al: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189.
13. Chen ZM, et al: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621.
14. Yusuf S, et al: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
15. Beinart SC, et al: Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005;46:761-769.
16. Mehta SR, et al: Effects of pretreatment with clopi-dogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
17. Montalescot G, et al: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938.
18. von Beckerath N, et al: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antit-hrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950.
19. Montalescot G, et al: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-731.
20. Cannon C P, et al: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375: 283-293.
21. Wijns W, et al: Guidelines on myocardial revascu-larization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-2555.
22. De Luca G, et al: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocar-dial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-1765.
23. Gershlick AH, et al: Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353:2758-2768.
24. Bassand J P, et al: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-1660.
25. Steinhubl SR, et al: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
26. Patrono C, Rocca B: The future of antiplatelet therapy in cardiovascular disease. Annu Rev Med 2010; 61:49-61.
27. Wiviott SD, et al: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
28. Wallentin L, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
29. Giugliano R P, et al: Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-2190.
30. Kastrati A, et al: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531-1538.
31. Camm AJ, et al: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
32. Friberg L, Hammar N, Rosenqvist M: Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967-975.
33. Bogousslavsky J, et al: Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants: the Lausanne Stroke Registry. Neurology 1991;41:855-859.
34. De Caterina R, Renda G: Atrial fibrillation: anti-thrombotic therapy; in Kristensen S, De Caterina R, Moliterno D (eds): Therapeutic Strategies in Thrombosis. Oxford, Clinical Publishing, 2006, pp 275-300.
35. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
36. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
37. Chimowitz MI, et al: Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke 1993;24:1015-1019.
38. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-988.
39. Hart RG, et al: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-1229.
40. Risk factors for stroke and efficacy of antithrom-botic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
41. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators: Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-1277.
42. Zabalgoitia M, et al: Transesophageal echocardio-graphic correlates of clinical risk of thromboembo-lism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622-1626.
43. The Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
44. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546-554.
45. Hughes M, Lip GY: Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295-304.
46. Gage B F, et al: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870.
47. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
48. Connolly SJ, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
49. Patel MR, Mahaffey K W, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
50. Granger CB, Alexander JH, McMurray JJ, et al: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
51. Hart RG, Benavente O, Pearce LA: Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999;9:215-217.
52. Mant J, et al: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
53. Rash A, et al: A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-156.
54. Connolly SJ, Eikelboom J, Joyner C, et al: Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
55. Connolly S, et al: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912.
56. Connolly SJ, et al: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078.